On 13-15 May 2011, the 9th International Conference for Organisations representing GIST and CML patients took place in Amsterdam. The conference provided patient advocate leaders with an opportunity for 3 days of learning, companionship and the chance to share experiences across borders. The conference welcomed 137 patient representatives (96 CML; 41 GIST) from 48 countries in Europe, North America, Asia, Australia, Africa, Middle East and Latin America.
Jean-Yves Blay is a sarcoma specialist and now president of the European Organisation for Research and Treatment of Cancer (EORTC), who is leading efforts to reshape cancer research so that every trial has a translational element that can build knowledge about the mechanisms driving the disease. In this cover story Blay talks to Cancer World about the challenges of bringing scientists and clinicians together to achieve these essential breakthroughs, given the tiny size of many of these sub populations. You can read the Cover Story here.
The assessment of Bayer HealthCare’s investigational drug regorafenib is to be fast-tracked by US authorities for the treatment of stomach tumours
The FDA’s fast-track designation is for metastatic and unresectable gastrointestinal stromal tumours (GIST) in patients whose disease has progressed despite being treated with at least Novartis’ Glivec (imatinib) and Pfizer’s Sutent (sunitinib).
A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy:
This multicenter phase II trial, supported by the Italian Sarcoma Group, was carried out to test the activity of the multikinase inhibitor sorafenib as second- or third-line therapy for patients with unresectable and relapsed high-grade osteosarcoma. In the last decades, only marginally effective therapies have been developed for such patients and most of them become candidates for either experimental therapies or supportive care.
Novartis discontinues clinical trial of Tasigna® for investigational use in newly diagnosed patients with unresectable and/or metastatic GISTApril 11, 2011 — Novartis announced today it is discontinuing a Phase III trial of Tasigna® (Nilotinib) for investigational use in the first-line treatment of gastrointestinal stromal tumors (GIST) based on the recommendation of an independent data monitoring committee. Interim results showed Tasigna® (Nilotinib) is unlikely to demonstrate superiority compared to Glivec® (Imatinib), the current standard of care in this setting.
“G.I.S.T.” - the first and unique survey assessing GIST patients’ compliance worldwide. The “GIST International Survey on Treatment” (G.I.S.T.) is the concrete outcome of a fruitful collaboration between a European network of medical experts: Conticanet, and the French GIST Patient Advocacy Group: AFPG “Ensemble contre le GIST”. Worldwide collaboration is crucial. “G.I.S.T.” needs your support! Please take a few minutes to complete the survey.
The 15th Annual Meeting of the Italian Sarcoma Group was held at 17-18 March in Ravenna, Italy. The Italian Sarcoma Group (ISG) is a non-profit, voluntary medical organization and was constituted in 1997. A special focus during the 2011 ISG Annual Meeting was dedicated to Patient Advocacy Groups (PAG) in Italy and was welcomed by patient advocates as a clear sign that the medical community acknowledges the importance of patient advocacy groups and is willing to build strategic alliances to reach common goals.
On 23 March 2011, the European Medicines Agency (EMA) and the European Commission announced the launch of the EU Clinical Trials Register (EU-CTR). The register will, for the first time, allow public access to information on interventional trials for medicines authorised in the 27 EU Member States as well as Iceland, Liechtenstein and Norway. The aim of this official public register is to make clinical research on pharmaceuticals more transparent for patients and others and to avoid unnecessary duplication of clinical trials. Get to the EU Clinical Trial Register.